SHINE Technologies, LLC (SHINE), a nuclear technology company, and ImaginAb Inc. (ImaginAb), a market-leading global biotechnology company focused on developing next-generation immuno-oncology imaging agents and therapeutic radiopharmaceuticals (RPT), recently announced the signing of a clinical supply agreement. Under the terms of this agreement, SHINE will provide ImaginAb with highly pure, non-carrier-added (n.c.a.) lutetium-177 (Lu-177) to support the company’s preclinical and clinical needs in the development of RPTs targeting various cancers.

SHINE’s Therapeutics division produces n.c.a. Lu-177, a low-energy beta-particle emitter, which can be paired with a targeting molecule (such as an antibody or peptide) to directly target and irradiate cancer cells. SHINE’s fusion technology and proprietary medical isotope production is expected to scale up without supply chain limitations experienced recently due to nuclear reactor shutdowns.

SHINE will begin supplying ImaginAb with n.c.a. Lu-177 immediately for the company’s development activities and for therapeutic clinical trials planned for 2023. More information on clinical trial results will be provided directly by ImaginAb.

To read more please visit:

SHINE Technologies and ImaginAb Announce Lutetium-177 Clinical Supply Agreement

Source: LG Display Newsroom